Inhalation Sciences Sweden AB (publ) (XSAT:ISAB)

Sweden · Delayed Price · Currency is SEK

0.1360

+0.0005 (0.37%)

At close: Sep 16, 2026

Market Cap	6.94M -89.5%
Revenue (ttm)	8.30M +55.0%
Net Income	-8.56M
EPS	-0.20
Shares Out	51.20M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,000
Open	0.1360
Previous Close	0.1355
Day's Range	0.1360 - 0.1360
52-Week Range	0.0608 - 0.5850
Beta	-0.25
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 24, 2026

About XSAT:ISAB

Inhalation Sciences Sweden AB (publ) develops and sells labtech equipment for inhalation research in Sweden. The company offers PreciseInhale, a laboratory system that allows scientists to measure how inhaled particles act in lungs and affect the health; DissolvIt, which enables in vitro simulation of dissolution and absorption of respirable particles in the lung epithelium; XposeALI, a 3D cell exposure module that combines aerosol capability with 3D cell models cultured at an air liquid interface; Nose-only inhalation, a standard method of exp... [Read more]

Industry Surgical and Medical Instruments and Apparatus

Founded 2004

Employees 5

Stock Exchange Spotlight Stock Market

Ticker Symbol ISAB

Full Company Profile

Financial Performance

In 2025, XSAT:ISAB's revenue was 3.04 million, a decrease of -72.47% compared to the previous year's 11.05 million. Losses were -10.16 million, 97.4% more than in 2024.

Financial Statements

News

Inhalation Sciences Sweden AB Transcript: Transcript

Q1 2026 revenue exceeded SEK 4 million, surpassing all of 2025, with SEK 2.5 million in new orders and a robust SEK 20 million pipeline. The M&A process is ongoing, aiming for completion before summer 2026, while regulatory changes in the U.S. present challenges.

21 days ago - Transcripts

Inhalation Sciences Sweden AB Transcript: Transcript

Q4 sales exceeded SEK 5 million, with a strong order pipeline driven by FDA collaboration and marketing efforts. An ongoing M&A process aims to unlock further value, while warrants and a guarantor secure liquidity during negotiations.

21 days ago - Transcripts

Inhalation Sciences Sweden AB Earnings Call Transcript: Q2 2026

Sales and revenue doubled year-over-year in H1 2026, with a strong SEK 30 million pipeline and new U.S. market activities. A SEK 4 million loan provides stability for ongoing M&A evaluation and continued growth.

23 days ago - Transcripts

Inhalation Sciences Sweden AB Quarterly report: Q2 2026

Inhalation Sciences Sweden AB has published its Q2 2026 quarterly earnings report on August 24, 2026.

23 days ago - Filings